SCHEMBL2333711

SCHEMBL2333711

CC(=O)Nc1ccc(C=Cc2ccc(N=C=S)cc2S(=O)(=O)O)c(S(=O)(=O)O)c1.[Na].[Na]

nearest known ligand 0.98

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAD51 Q06609 5/20 0.80
RAD1 O60671 1/20 0.70
P2RY6 Q15077 1/20 0.70
ENPP2 Q13822 2/20 0.66
APEX1 P27695 1/20 0.57
ALDH1A1 P00352 3/20 0.53
KDM4E B2RXH2 2/20 0.53
USP2 O75604 2/20 0.53
LTA P01374 2/20 0.53
CYP3A4 P08684 2/20 0.53
MAPT P10636 2/20 0.53
HPGD P15428 2/20 0.53
P2RX3 P56373 2/20 0.53
HSD17B10 Q99714 2/20 0.53
TDP1 Q9NUW8 2/20 0.53
SENP3 Q9H4L4 4/20 0.42
SENP2 Q9HC62 4/20 0.42
SENP1 Q9P0U3 4/20 0.42
SUMO2 P61956 3/20 0.42
SUMO1 P63165 3/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30160852 1.00 RAD51 (0.80) RAD51RAD1P2RY6ENPP2APEX1
SCHEMBL25796 0.99 RAD51 (0.81) RAD51RAD1P2RY6ENPP2APEX1
SCHEMBL29351606 0.99 RAD51 (0.81) RAD51RAD1P2RY6ENPP2APEX1
SCHEMBL175934 0.99 RAD51 (0.81) RAD51RAD1P2RY6ENPP2APEX1
SCHEMBL15823509 0.98 RAD51 (0.80) RAD51RAD1P2RY6ENPP2APEX1
SCHEMBL2333703 0.98 RAD51 (0.80) RAD51RAD1P2RY6ENPP2APEX1
SCHEMBL5616054 0.91 RAD51 (0.70) RAD51RAD1P2RY6ENPP2APEX1
Acridine SCHEMBL722533 0.89 RAD51 (0.67) RAD51RAD1P2RY6ENPP2APEX1
Acridine SCHEMBL6290391 0.89 RAD51 (0.67) RAD51RAD1P2RY6ENPP2APEX1
SCHEMBL4857681 0.88 ENPP2 (0.69) RAD51RAD1P2RY6ENPP2APEX1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130189280-A1 PROTEIN DOMAINS AND USES THEREFOR SYDNEY WEST AREA HEALTH SERVICE (SWAHS) (AU) 2013-07-25 US disclosed
EP-2533794-A1 PROTEIN DOMAINS AND USES THEREFOR The University Of Sydney (AU) 2012-12-19 EP disclosed
WO-2011097688-A1 PROTEIN DOMAINS AND USES THEREFOR THE UNIVERSITY OF SYDNEY (AU) 2011-08-18 WO disclosed
US-7419818-B2 Organic conductor FUJI XEROX CO., LTD (JP) 2008-09-02 US disclosed
US-20070244309-A1 Organic conductor FUJI XEROX CO., LTD. (JP) 2007-10-18 US disclosed
US-7238794-B2 Organic conductor FUJI XEROX CO., LTD. (JP) 2007-07-03 US disclosed
US-20030170692-A1 Organic conductor FUJI XEROX CO., LTD. (JP) 2003-09-11 US disclosed
EP-1324352-A2 Organic conductor FUJI XEROX CO., LTD. (JP) 2003-07-02 EP disclosed
US-5512667-A Trifunctional intermediates for preparing 3'-tailed oligonucleotides DRUG ROYALTY LP1 (CA) 1996-04-30 US disclosed
US-5419966-A Solid support for synthesis of 3'-tailed oligonucleotides MICROPROBE CORPORATION (US) 1995-05-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030170692-A1 Organic conductor DNMT1, DNMT3A, POLN RAD51 932/4885RAD1 1509/4885P2RY6 1326/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.